- Home
- RGT vs IMAB Comparison
RGT vs IMAB Comparison
Compare RGT & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGT
- IMAB
- Stock Information
- Founded
- RGT 1986
- IMAB 2014
- Country
- RGT United States
- IMAB United States
- Employees
- RGT N/A
- IMAB N/A
- Industry
- RGT Trusts Except Educational Religious and Charitable
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- RGT Finance
- IMAB Health Care
- Exchange
- RGT Nasdaq
- IMAB Nasdaq
- Market Cap
- RGT 67.6M
- IMAB 79.9M
- IPO Year
- RGT N/A
- IMAB 2020
- Fundamental
- Price
- RGT $11.18
- IMAB $0.97
- Analyst Decision
- RGT
- IMAB Strong Buy
- Analyst Count
- RGT 0
- IMAB 3
- Target Price
- RGT N/A
- IMAB $8.00
- AVG Volume (30 Days)
- RGT 22.4K
- IMAB 270.1K
- Earning Date
- RGT 01-01-0001
- IMAB 03-13-2025
- Dividend Yield
- RGT 1.43%
- IMAB N/A
- EPS Growth
- RGT N/A
- IMAB N/A
- EPS
- RGT 0.92
- IMAB N/A
- Revenue
- RGT N/A
- IMAB $569,464.00
- Revenue This Year
- RGT N/A
- IMAB N/A
- Revenue Next Year
- RGT N/A
- IMAB N/A
- P/E Ratio
- RGT $11.42
- IMAB N/A
- Revenue Growth
- RGT N/A
- IMAB N/A
- 52 Week Low
- RGT $7.84
- IMAB $0.84
- 52 Week High
- RGT $11.08
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- RGT 54.57
- IMAB 46.51
- Support Level
- RGT $11.19
- IMAB $0.96
- Resistance Level
- RGT $11.29
- IMAB $1.04
- Average True Range (ATR)
- RGT 0.12
- IMAB 0.05
- MACD
- RGT 0.01
- IMAB -0.00
- Stochastic Oscillator
- RGT 76.56
- IMAB 36.36
About RGT Royce Global Value Trust Inc.
Royce Global Value Trust Inc is a diversified closed-end investment company. The fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples, and energy. Geographically, it has presence in the region of the United Kingdom, Japan, the United States, Canada, France, Hong Kong, and Germany.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).